Kura Oncology, Inc. (Nasdaq: KURA), a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE